KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbCellera Biologics (ABCL) Receivables - Other: 2020-2021

  • AbCellera Biologics' Receivables - Other was N/A to $62.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $62.1 million, marking a year-over-year change of. This contributed to the annual value of $212.3 million for FY2020, which is N/A change from last year.
  • As of Q2 2021, AbCellera Biologics' Receivables - Other stood at $62.1 million, which was down 67.84% from $193.1 million recorded in Q1 2021.
  • Over the past 5 years, AbCellera Biologics' Receivables - Other peaked at $212.3 million during Q4 2020, and registered a low of $62.1 million during Q2 2021.
  • For the 2-year period, AbCellera Biologics' Receivables - Other averaged around $155.8 million, with its median value being $193.1 million (2021).